Lipopolysaccharide induces inflammation and facilitates lung metastasis in a breast cancer model via the prostaglandin E2-EP2 pathway

Molecular Medicine Reports

Volumn 11, Issue 6, 2015, Pages 4454-4462

  Li, Shancheng ^a   Xu, Xiaoya ^a   Jiang, Man ^a   Bi, Yuli ^a   Xu, Jiying ^a   Han, Mingyong ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Angiogenesis; Breast cancer; Lung metastasis; Prostaglandin E2 EP2; Vascular endothelial growth factor

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; 8 OXOGUANINE DNA GLYCOSYLASE 1; BETA ACTIN; DNA GLYCOSYLTRANSFERASE; MESSENGER RNA; UNCLASSIFIED DRUG; 6-ISOPROPOXY-9-OXOXANTHENE-2-CARBOXYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYTOKINE; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; VASCULOTROPIN A; XANTHONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DNA STRAND BREAKAGE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HYPEROXIA; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG DYSPLASIA; NEWBORN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; BLOOD VESSEL; BREAST TUMOR; CELL CULTURE; CELL PROLIFERATION; CHEMICALLY INDUCED; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; INFLAMMATION; LUNG; LUNG NEOPLASMS; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; SECONDARY; VASCULARIZATION;

ANIMALIA; MURINAE; MUS;

ANIMALS; BLOOD VESSELS; BREAST NEOPLASMS; CELECOXIB; CELL PROLIFERATION; CELLS, CULTURED; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; INFLAMMATION; LIPOPOLYSACCHARIDES; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, PROSTAGLANDIN E; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XANTHONES;

EID: 84924674617     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3258     Document Type: Article

References (42)

1. Liu H, Kato Y, Erzinger SA, Kiriakova GM, Qian Y, Palmieri D, Steeg PS and Price JE: The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer 12: 583, 2012.
2. Lee YT: Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 23: 175-180, 1983.
3. DeSantis C, Siegel R, Bandi P and Jemal A: Breast cancer statistics, 2011. CA Cancer J Clin 61: 409-418, 2011.
4. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, Bouchier-Hayes D and Dong Z: Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 101: 415-422, 2002.
5. Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, Wada J, Yanai K, Koga K, Sato N, Kubo M, Tanaka M, Onishi H and Katano M: Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. J Surg Oncol 100: 725-731, 2009.
6. He W, Liu Q, Wang L, Chen W, Li N and Cao X: TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol 44: 2850-2859, 2007.
7. Gassmann P, Hemping-Bovenkerk A, Mees ST and Haier J: Metastatic tumor cell arrest in the liver-lumen occlusion and specific adhesion are not exclusive. Int J Colorectal Dis 24: 851-858, 2009.
8. He Z, Zhu Y and Jiang H: Inhibiting toll-like receptor 4 signaling ameliorates pulmonary fi brosis during acute lung injury induced by lipopolysaccharide: an experimental study. Respir Res 10: 126, 2009.
9. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, Kudo E, Shimada M and Santo T: High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 102: 908-915, 2010.
10. Yan L, Cai Q and Xu Y: The ubiquitin-CXCR4 axis plays an important role in acute lung infection-enhanced lung tumor metastasis. Clin Cancer Res 19: 4706-4716, 2013.
11. Killeen SD, Wang JH, Andrews EJ and Redmond HP: Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system. Br J Cancer 100: 1589-1602, 2009.
12. Liu X, Liang J and Li G: Lipopolysaccharide promotes adhesion and invasion of hepatoma cell lines HepG2 and HepG2.2.15. Mol Biol Rep 37: 2235-2239, 2010.
13. Brown DM and Ruoslahti E: Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 5: 365-374, 2004.
14. Zhao Y, Kong X, Li X, Yan S, Yuan C, Hu W and Yang Q: Metadherin mediates lipopolysaccharide-induced migration and invasion of breast cancer cells. PLoS One 6: e29363, 2011.
15. Sethi G, Shanmugam MK, Ramachandran L, Kumar AP and Tergaonkar V: Multifaceted link between cancer and inflammation. Biosci Rep 32: 1-15, 2012.
16. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS and Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983.
17. Doan HQ, Bowen KA, Jackson LA and Evers BM: Toll-like receptor 4 activation increases Akt phosphorylation in colon cancer cells. Anticancer Res 29: 2473-2478, 2009.
18. Wang L, Liu Q, Sun Q, Zhang C, Chen T and Cao X: TLR4 signaling in cancer cells promotes chemoattraction of immature dendritic cells via autocrine CCL20. Biochem Biophys Res Commun 366: 852-856, 2008.
19. Ferrara N and Henzel WJ: Pituitary follicular cells secrete a novel heparin-binding growth factor specifi c for vascular endothelial cells. Biochem Biophys Res Commun1 61: 851-858, 1989.
20. Tsuji T, Aoshiba K, Yokohori N and Nagai A: A systemically administered EP2 receptor agonist stimulates pulmonary angiogenesis in a murine model of emphysema. Prostaglandins Other Lipid Mediat 90: 85-88, 2009.
21. Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K and Shibuya M: Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann NY Acad Sci 902: 201-207, 2000.
22. Lohela M, Bry M, Tammela T and Alitalo K: VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol 21: 154-165, 2009.
23. Perrot-Applanat M and Di Benedetto M: Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. Cell Adh Migr 6: 547-553, 2012.
24. Koch AE: Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 62: ii60-ii67, 2003.
25. Baeriswyl V and Christofori G: The angiogenic switch in carcinogenesis. Semin Cancer Biol 19: 329-337, 2009.
26. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl 3): 4-10, 2005.
27. Nakanishi M, Sato T, Li Y, Nelson AJ, Farid M, Michalski J, Kanaji N, Wang X, Basma H, Patil A, Goraya J, Liu X, Togo S, L Toews M, Holz O, Muller KC, Magnussen H and Rennard SI: Prostaglandin E2 stimulates the production of vascular endothelial growth factor through the E-prostanoid-2 receptor in cultured human lung fi broblasts. Am J Respir Cell Mol Biol 46: 217-223, 2012.
28. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM and Peters-Golden M: Prostaglandin E2 inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol 292: L405-L413, 2007.
29. Sakurai T, Tamura K, Okamoto S, Hara T and Kogo H: Possible role of cyclooxygenase II in the acquisition of ovarian luteal function in rodents. Biol Reprod 69: 835-842, 2003.
30. Sakurai T, Tamura K and Kogo H: Stimulatory effects of eicosanoids on ovarian angiogenesis in early luteal phase in cyclooxygenase-2 inhibitor-treated rats. Eur J Pharmacol 516: 158-164, 2005.
31. Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP and Versteeg HH: Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36: 1187-1205, 2004.
32. Sakurai T, Tamura K and Kogo H: Vascular endothelial growth factor increases messenger RNAs encoding cyclooxygenase and membrane-associated prostaglandin E synthase in rat luteal cells. J Endocrinol 183: 527-533, 2004.
33. Folkman J and D'Amore PA: Blood vessel formation: what is its molecular basis? Cell 87: 1153-1155, 1996.
34. Keith RL, Geraci MW, Nana-Sinkam SP, Breyer RM, Hudish TM, Meyer AM, Malkinson AM and Dwyer-Nield LD: Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. Anticancer Res 26: 2857-2861, 2006.
35. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF and Hla T: Role of prostaglandin E2dependent angiogenic switch in cyclooxygenase 2induced breast cancer progression. Proc Natl Acad Sci USA 101: 591-596, 2004.
36. Gately S and Li WW: Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 31: 2-11, 2004.
37. Ma X, Kundu N, Ioffe OB, et al: Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Mol Cancer Res 8: 1310-1318, 2010.
38. Narumiya S, Sugimoto Y and Ushikubi F: Prostanoid receptors: structures, properties and functions. Physiol Rev 79: 1193-1226, 1999.
39. Yang T and Du Y: Distinct roles of central and peripheral prostaglandin E2 and EP subtypes in blood pressure regulation. Am J Hypertens 25: 1042-1049, 2012.
40. Sugimoto Y and Narumiya S: Prostaglandin E receptors. J Biol Chem 282: 11613-11617, 2007.
41. Breyer RM, Bagdassarian CK, Myers SA and Breyer MD: Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 41: 661-690, 2001.
42. Chell S, Kaidi A, Williams AC and Paraskeva C: Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta 1766: 104-119, 2006.